These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 7506953)
21. Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates. Fishwild DM; Wu HM; Carroll SF; Bernhard SL Clin Exp Immunol; 1994 Jul; 97(1):10-8. PubMed ID: 8033405 [TBL] [Abstract][Full Text] [Related]
22. Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization. Faguet GB; Agee JF Blood; 1993 Jul; 82(2):536-43. PubMed ID: 7687163 [TBL] [Abstract][Full Text] [Related]
23. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents. Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572 [TBL] [Abstract][Full Text] [Related]
24. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents. Jachez B; Loor F Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300 [TBL] [Abstract][Full Text] [Related]
25. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Weil-Hillman G; Runge W; Jansen FK; Vallera DA Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376 [TBL] [Abstract][Full Text] [Related]
26. Enhancement of ricin toxin A chain immunotoxin activity: synthesis, ionophoretic ability, and in vitro activity of monensin derivatives. Dosio F; Franceschi A; Ceruti M; Brusa P; Cattel L; Colombatti M Biochem Pharmacol; 1996 Jul; 52(1):157-66. PubMed ID: 8678901 [TBL] [Abstract][Full Text] [Related]
27. Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin. Siena S; Villa S; Bregni M; Bonnadonna G; Gianni AM Blood; 1987 Jan; 69(1):345-8. PubMed ID: 3098324 [TBL] [Abstract][Full Text] [Related]
28. Sensitivity of human leukemia cells in exponential or stationary growth phase to anti-CD5 immunotoxins. Role of intracellular processing events. Chignola R; Anselmi C; Franceschi A; Pasti M; Candiani C; Tridente G; Colombatti M J Immunol; 1994 Mar; 152(5):2333-43. PubMed ID: 7510743 [TBL] [Abstract][Full Text] [Related]
29. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2. Better M; Bernhard SL; Lei SP; Fishwild DM; Lane JA; Carroll SF; Horwitz AH Proc Natl Acad Sci U S A; 1993 Jan; 90(2):457-61. PubMed ID: 7678457 [TBL] [Abstract][Full Text] [Related]
30. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Friche E; Jensen PB; Nissen NI Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375 [TBL] [Abstract][Full Text] [Related]
31. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Jiang XR; Kelsey SM; Wu YL; Newland AC Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760 [TBL] [Abstract][Full Text] [Related]
32. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. Youle RJ; Uckun FM; Vallera DA; Colombatti M J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of anti-CD5 F(ab')2 and Fab' immunoconjugates in human peripheral blood lymphocyte-reconstituted severe combined immunodeficient mice. Kohn FR; Fishwild DM; Bernhard SL; Better M; Kung AH Int J Immunopharmacol; 1993 Nov; 15(8):871-8. PubMed ID: 7504661 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562 [TBL] [Abstract][Full Text] [Related]
35. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin. Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798 [TBL] [Abstract][Full Text] [Related]
36. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Rostaing-Capaillon O; Casellas P Cancer Res; 1990 May; 50(10):2909-16. PubMed ID: 1692250 [TBL] [Abstract][Full Text] [Related]
37. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity. Chiron M; Jaffrezou JP; Carayon P; Bordier C; Roubinet F; Xavier C; Brandely M; Laurent G Clin Exp Immunol; 1990 Nov; 82(2):214-20. PubMed ID: 2122930 [TBL] [Abstract][Full Text] [Related]
39. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794 [TBL] [Abstract][Full Text] [Related]
40. Sensitivity of human glioma cells to cytotoxic heteroconjugates. Colombatti M; Bisconti M; Dell'Arciprete L; Gerosa MA; Tridente G Int J Cancer; 1988 Sep; 42(3):441-8. PubMed ID: 3138194 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]